Pfizer RSV vaccine gets off to fast start on market

The pharma’s shot Abrysvo made over $300 million in sales during the first few months of its launch, and will be an important product to help offset declining COVID vaccine sales.

Delilah Alvarado Member since October 31, 2023

Loading + Follow Following